Artivion, Inc. (NYSE:AORT - Get Free Report) CAO Amy Horton sold 641 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $38.02, for a total transaction of $24,370.82. Following the completion of the transaction, the chief accounting officer directly owned 132,514 shares of the company's stock, valued at approximately $5,038,182.28. The trade was a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amy Horton also recently made the following trade(s):
- On Tuesday, February 24th, Amy Horton sold 830 shares of Artivion stock. The stock was sold at an average price of $35.69, for a total value of $29,622.70.
- On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The stock was sold at an average price of $37.59, for a total value of $65,068.29.
- On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The shares were sold at an average price of $44.42, for a total value of $203,088.24.
Artivion Stock Performance
Artivion stock opened at $38.56 on Wednesday. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The stock has a 50 day moving average of $41.59 and a 200-day moving average of $42.95. The stock has a market cap of $1.85 billion, a P/E ratio of 192.81 and a beta of 1.60. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25.
Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business's revenue was up 19.2% compared to the same quarter last year. On average, analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.
Institutional Trading of Artivion
Several large investors have recently added to or reduced their stakes in the business. Invesco Ltd. increased its holdings in shares of Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company's stock valued at $50,228,000 after purchasing an additional 748,119 shares during the period. XTX Topco Ltd acquired a new position in Artivion during the 4th quarter valued at about $746,000. Susquehanna Portfolio Strategies LLC raised its position in shares of Artivion by 21.5% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company's stock worth $1,849,000 after buying an additional 7,186 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Artivion in the 4th quarter worth approximately $248,000. Finally, Millennium Management LLC boosted its holdings in shares of Artivion by 1.0% in the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company's stock valued at $4,188,000 after acquiring an additional 893 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.
More Artivion News
Here are the key news stories impacting Artivion this week:
- Positive Sentiment: Analysts maintain a constructive view — the consensus rating reported is "Moderate Buy," and several firms have reiterated buy/outperform ratings and mid‑to‑high price targets, which can support demand for AORT shares. Artivion Receives Consensus Rating
- Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference (fireside chat), giving the company a chance to update guidance, product progress or commercialization milestones — an event that often attracts buy‑side attention. Artivion to Participate in Oppenheimer Conference
- Positive Sentiment: Institutional investors have been adding to positions (Invesco, Summit Partners, Goldman Sachs, Two Sigma among those increasing exposure), which can provide steady bid support and signal confidence from larger, professional investors. MarketBeat - Artivion Institutional Activity
- Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates (Feb. 12), showing top‑line growth; this underpins the bull case but may already be priced in given prior analyst upgrades. MarketBeat - Artivion Earnings Summary
- Negative Sentiment: Multiple senior insiders sold shares on March 2 (CEO James Mackin sold ~14.9k shares; EVP Lance Berry and several SVPs also sold), a cluster of sales that markets often interpret as a negative signal even though insiders retain large holdings. See the SEC Form 4 for details. SEC Form 4 - Mackin
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Wall Street Zen cut shares of Artivion from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Oppenheimer reaffirmed an "outperform" rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Canaccord Genuity Group dropped their price objective on shares of Artivion from $51.00 to $48.00 and set a "buy" rating on the stock in a research note on Friday, February 13th. Finally, Weiss Ratings upgraded Artivion from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, February 20th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.97.
Check Out Our Latest Research Report on AORT
Artivion Company Profile
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
